Journal
CURRENT OPINION IN GASTROENTEROLOGY
Volume 22, Issue 4, Pages 361-364Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mog.0000231808.10773.8e
Keywords
Crohn's disease; interleukin-12; interieukin-13; interieukin-21; interleukin-22; NKT cells; T cells; ulcerative colitis
Categories
Ask authors/readers for more resources
Purpose of review In both Crohn's disease and ulcerative I colitis, the tissue damage results from an inappropriate or exaggerated immune response to antigens of the gut microflora. This review summarizes current knowledge regarding the role of immune-inflammatory mediators in the pathogenesis of inflammatory bowel disease. Recent findings Despite having a common basis in overresponsiveness to luminal antigens, Crohn's disease and ulcerative colitis are immunologically distinct entities. Crohn's disease is associated with a Th1 T cell-mediated response, characterized by enhanced production of interferon-gamma and tumor necrosis factor-alpha. Interleukin (IL)-12 and, possibly, IL-23 govern the, Th1 cell differentiation, but optimal induction and stabilization of polarized Thl cells would require additional cytokines, such as IL-15, IL-18 and IL-21. In ulcerative colitis, the local immune response is less polarized, but it is characterized by CD1-reactive natural killer T cell production of IL-13. Beyond these differences, Crohn's disease and ulcerative colitis share important end-stage effector pathways of intestinal injury, which are mediated by an active cross-talk between immune and non-immune mucosal cells. Summary The clarification of the complex network of immune-inflammatory mediators operating in the gut of patients with inflammatory bowel disease has led to the identification of new targets that could, in turn, drive the development of effective biological therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available